関連する実験動画
Updated: Jun 9, 2025
06:40
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
Published on: June 29, 2019
6.6K
胃潰瘍 の 病気 - 概要
1University of Wisconsin School of Medicine and Public Health, Madison.
JAMA
|October 28, 2024
まとめ
H.ピロリやNSAIDによって引き起こされる胃潰瘍は,多くの患者に影響します. 治療には酸性阻害剤とH. pyloriの根絶が含まれており,再発を大幅に減らすことができます.
科学分野:
- 胃腸内科
- 内科 医学
- 流行病学
背景:
- 胃潰瘍疾患 (PUD) は米国の人口の1%に感染し,毎年54,000人が出血のために入院しています.
- 主治医の腹部上部の痛みはしばしばPUDによって引き起こされます.
- 主な原因はヘリコバクター・パイロリ (42%) とNSAID使用 (36%) です.
研究 の 目的:
- 胃潰瘍の流行病学,原因,合併症,診断,治療についてまとめます.
- 潰瘍の治癒と再発の予防における 現在の治療法の有効性を強調する.
主な方法:
- PUDの流行,原因,結果に関する文献レビューと疫学データの合成.
- 酸性抑制,H. pyloriの根絶,NSAIDの管理を含む,PUDの治療効果の分析
主要な成果:
- PUDの合併症には出血 (73%),穿孔 (9%),阻害 (3%) が含まれており,米国では年間10,000人が死亡しています.
- プロトンポンプ阻害剤 (オメプラゾールなど) は4~8週間で80~100%の潰瘍を治します.
- H. pyloriの根絶は再発を50- 60%から0- 2%に減少させ,NSAIDの投与を中止すると,潰瘍の95%が治り,再発は40%から9%に減少します.
結論:
- PUDは罹病率と死亡率の重要な原因です.
- プロトンポンプ阻害剤は 潰瘍を治す主な治療法です
- 再発を防ぐには,H. pyloriの根絶と,賢明なNSAIDの使用または併用療法が必要です.
関連する概念動画
01:30Peptic Ulcer Disease I: Introduction
139
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
139
01:26Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74
01:28Peptic Ulcer Disease II: Pathophysiology
303
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
303
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
356
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
356
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
362
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
362
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
91
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
91